2020
DOI: 10.2147/tcrm.s292504
|View full text |Cite|
|
Sign up to set email alerts
|

Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
26
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 27 publications
(30 citation statements)
references
References 125 publications
(222 reference statements)
1
26
0
3
Order By: Relevance
“…8 Considering that JAK-inhibitors target several cytokine pathways instead of one single pathway, we hypothesized that this could be an effective therapy for the majority of CHE patients. 1,7 Our hypothesis was strengthened by previous literature on three different JAK-inhibitors that showed promising efficacy on CHE. Recently, two phase 3 trials with upadacitinib, an oral JAK-1 inhibitor, presented significant improvements in mild-to-severe CHE in patients with moderateto-severe AD compared to placebo at 16 weeks.…”
Section: Discussionsupporting
confidence: 52%
See 2 more Smart Citations
“…8 Considering that JAK-inhibitors target several cytokine pathways instead of one single pathway, we hypothesized that this could be an effective therapy for the majority of CHE patients. 1,7 Our hypothesis was strengthened by previous literature on three different JAK-inhibitors that showed promising efficacy on CHE. Recently, two phase 3 trials with upadacitinib, an oral JAK-1 inhibitor, presented significant improvements in mild-to-severe CHE in patients with moderateto-severe AD compared to placebo at 16 weeks.…”
Section: Discussionsupporting
confidence: 52%
“… 8 Considering that JAK‐inhibitors target several cytokine pathways instead of one single pathway, we hypothesized that this could be an effective therapy for the majority of CHE patients. 1 , 7 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Существует значительная неудовлетворенная потребность в эффективных терапевтических стратегиях долгосрочного контроля за течением хронической экземы. Согласно статистическим данным после 5 лет лечения различными топическими средствами примерно 65% пациентов имеют непрерывно рецидивирующее течение [4,23,24]. Топические глюкокортикостероиды (ГКС) на сегодняшний день являются средством выбора для лечения хронической экземы кистей рук [22][23][24][25].…”
Section: лечениеunclassified
“…Согласно статистическим данным после 5 лет лечения различными топическими средствами примерно 65% пациентов имеют непрерывно рецидивирующее течение [4,23,24]. Топические глюкокортикостероиды (ГКС) на сегодняшний день являются средством выбора для лечения хронической экземы кистей рук [22][23][24][25]. Однако длительное применение топических ГКС может препятствовать восстановлению рогового слоя эпидермиса за счет нарушения синтеза липидов и вызывать атрофию кожи [26].…”
Section: лечениеunclassified